• Prospective Randomized Optical Coherence Tomography Oslo tRial

  NCT02337348

  TerminatedInterventionalNot ApplicableUpdated Sep 3, 2019
• Starring Optical Coherence Tomography During Percutaneous Coronary Intervention Guidance

  NCT07182799

  Active, not recruitingObservationalUpdated Sep 19, 2025
• Randomized Controlled Study of the Traditional Percutaneous Coronary Intervention and Intervention Using Optical Coherence Tomography of Incomplete Stent Adhesion and Extent of the Formation of Neointima by Resolute Zotarolimus-eluting Stent Insertion

  NCT01869842

  Unknown statusInterventionalNot ApplicableUpdated Jun 5, 2013
• Optical Coherence Tomography Versus Intravascular Ultrasound Guided Percutaneous Coronary Intervention

  NCT03394079

  Active, not recruitingInterventionalNot ApplicableUpdated Jan 2, 2026
• Optical Coherence Tomography Guided Percutaneous Coronary Intervention for Drug-eluting In-stent Restenosis

  NCT03809754

  Unknown statusInterventionalNot ApplicableUpdated Jan 23, 2019
• Morphological Parameters of In-stent RESTenosis Assessed and Identified by OCT

  NCT04268875

  CompletedInterventionalNot ApplicableUpdated Apr 18, 2023

ClinicalTrials.gov ID

NCT06779110

Lead Sponsor

San Luigi Gonzaga HospitalOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

360Estimated

Last Update Posted

Jan 16, 2025Actual

Start Date

Sep 1, 2024Actual

Primary Completion Date

Sep 1, 2027Estimated

Completion Date

Sep 1, 2028Estimated

Official Title

IN-Stent RestenosIs Detection and TrEtment by Optical Coherence Tomography

Brief Summary

Although advances in drug-eluting stents (DES) have substantially reduced the risk of coronary in-stent restenosis (ISR) and the need for target lesion revascularisation (TLR), ISR persists. There are several treatment options for ISR (conventional balloon angioplasty, cutting or scoring balloons, drug-coated balloons, repeat DES implantation or bypass surgery). Coronary imaging is mandatory to perform PCI on ISR. Optimal coherence tomography (OCT) is an excellent option to guide PCI, but its role in ISR-PCI remains unclear. The INSIDE OCT Trial aims to compare the acute performance of PCI for ISR, either guided by OCT and angiography or by angiography alone.

Detailed Description

INSIDE-OCT is an investigator-initiated, randomised, multicenter, non-blinded trial.

Patients presenting with acute coronary syndrome or stable ischemic heart disease and ISR (angiographic stenosis between 70% and 99% in at least two projections, in a vessel with a lumen diameter ≥ 2.25 - ≤ 5.75 mm) with PCI indication will be randomised (1:1) to undergo either PCI guided by OCT (Group 1) or PCI with angiographic guidance only (Group 2).

Nowadays, PCI is performed following current guidelines and clinical practice. Any manoeuvre is left to the operator's discretion. Any approved intracoronary gears could be used (multiple wires, compliant, non-compliant, cutting, scoring balloons, Drug coated balloons, new stents implantation etc.).

Randomisation will be performed on the online eCRF site immediately after the end of the diagnostic angiography after acquiring the patient's study informed consent and after reviewing inclusion/exclusion criteria.

Randomisation will generate two groups:

PCI of ISR guided by OCT (group 1): in this case, the operator has to perform at least one OCT run before and one OCT run at the end of PCI. The operator is left free to review the OCT run in the console directly and is left free to perform during PCI any additional OCT run.

PCI of ISR guided by angiography (group 2): in this case, the operator has to perform PCI following angiography. To allow outcome computation, OCT will also be performed in this group at the beginning and the end of PCI. However, the operator will be wholly blinded to any OCT findings. A detailed description of the blinding modality is reported in the following paragraph.

Blinding: In Group 2, OCT will be performed at the beginning of the procedure, although the operator will be blinded to any OCT findings. In practice, the operator will perform OCT pullback properly, advancing the probe in the target vessel following angio guidance but without viewing the OCT monitor in the cath lab. A trained nurse/technician not involved in any decision regarding the procedure will guide the operator to perform an OCT pullback correctly and will check immediately if the OCT run is consistent with the current standard of quality. The operator could not receive any information from the OCT run recorded at this stage and had to proceed with the PCI procedure with angio-only guidance Therefore, the operator will declare the end of the procedure after completing all PCI manoeuvres judged necessary to obtain an excellent angiographic result. At this stage, an OCT pullback will be performed again to appraise OCT final data required for primary endpoint computation.

Therefore, the operator should evaluate the OCT runs, and he will be left free to perform additional PCI manoeuvres to optimise the result if necessary.

In groups 1 and 2, the operator should detail his PCI planned strategy before and after OCT runs. Changes in PCI planning after OCT disclosure will be recorded in both groups (see secondary outcomes).

• Coronary Artery Disease
• Stent Restenosis
• STENT

• Percutaneous Coronary Intervention

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Informed consent signed
• Age ≥ 18 years
• Referred for angiography either in stable or ACS setting suitability for PCI through femoral or radial access
• A coronary in-stent restenosis between 70% and 99% in at least two projections in a vessel with a lumen diameter ≥ 2.25 - ≤ 5.75 mm (The severity of the stenosis should be based on visual estimation, with current online state-of-the-art angiographic equipment of the participating centres and after a mandatory dose of 50-200 mcg intracoronary of nitroglycerine.
• Stable hemodynamics

Exclusion Criteria:

• Inability to give informed consent
• Participation in another clinical study with an investigational product
• OCT pullback not technically feasible in vessel site

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Single

Lead Sponsor

San Luigi Gonzaga HospitalOTHER

monica.verdoia@gmail.com0039 015 15151